J&J drug shows promise when combined with Truvada for HIV

07/22/2010 | Reuters

Two studies found that using Johnson & Johnson's experimental HIV drug rilpivirine in combination with Gilead Sciences' Truvada worked as well as using Gilead's Atripla or similar medicines alone, with fewer adverse effects. However, 9% of HIV patients failed to respond to the combination treatment, compared with 4.8% of those treated with an older drug.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC